Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cybin ( (TSE:CYBN) ) has provided an update.
Cybin Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting a successful $175 million financing round led by biopharmaceutical investors. The company is progressing with its Phase 2 and Phase 3 clinical trials for CYB004 and CYB003, targeting GAD and MDD respectively, with key data readouts expected in 2026. The recent financing has strengthened Cybin’s cash position, enabling it to advance its late-stage programs, prepare for commercialization, and retire debt. The company is also expanding its intellectual property portfolio, which supports its competitive positioning in the neuropsychiatry sector.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is involved in advancing clinical trials for therapies targeting disorders such as Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
For an in-depth examination of CYBN stock, go to TipRanks’ Overview page.